Neurocrine Biosciences (NBIX) Total Current Liabilities (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Total Current Liabilities of $874.5 million for Q2 2026, up 60.08% year-over-year from $546.3 million in Q2 2025, and up 5.15% on a QoQ basis from $831.7 million in Q1 2026.
Neurocrine Biosciences (NBIX) Total Current Liabilities (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Total Current Liabilities for 17 years, with the latest figure at $874.5 million in Q2 2026.
- Total Current Liabilities for Q2 2026 came in at $874.5 million, up 60.08% year-over-year; the trailing twelve-month figure through Jun 2026 was $874.5 million (up 60.08% YoY), and the FY2025 annual result was $743.4 million, up 46.43% from the prior year.
- Total Current Liabilities advanced to $874.5 million in Q2 2026, from $831.7 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $874.5 million in Q2 2026 and troughed at $253.5 million in Q1 2022.
- A 5-year average of $559.5 million and a median of $542.0 million in 2022 frame the typical range for Total Current Liabilities.
- The widest annual swing landed in 2022, when Total Current Liabilities surged 118.76%; it then sank 37.87% in 2024.
- A 5-year view of Total Current Liabilities shows it stood at $537.7 million in 2022, then increased by 21.78% to $654.8 million in 2023, then fell by 22.46% to $507.7 million in 2024, then surged by 46.43% to $743.4 million in 2025, then climbed by 17.64% to $874.5 million in 2026.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $874.5 million in Q2 2026, $831.7 million in Q1 2026, and $743.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.11 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 43.27 Bn | 39.61 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.81 Bn | 30.14 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.72 Bn | 22.92 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 1.79 Bn |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | 662.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 874.50 Mn |
| Mar 31, 2026 | 831.70 Mn |
| Dec 31, 2025 | 743.40 Mn |
| Sep 30, 2025 | 638.00 Mn |
| Jun 30, 2025 | 546.30 Mn |
| Mar 31, 2025 | 522.90 Mn |
| Dec 31, 2024 | 507.70 Mn |
| Sep 30, 2024 | 429.70 Mn |
| Jun 30, 2024 | 398.50 Mn |
| Mar 31, 2024 | 712.90 Mn |
| Dec 31, 2023 | 654.80 Mn |
| Sep 30, 2023 | 691.60 Mn |
| Jun 30, 2023 | 582.50 Mn |
| Mar 31, 2023 | 374.10 Mn |
| Dec 31, 2022 | 537.70 Mn |
| Sep 30, 2022 | 485.10 Mn |
| Jun 30, 2022 | 285.70 Mn |
| Mar 31, 2022 | 253.50 Mn |
| Dec 31, 2021 | 245.80 Mn |
| Sep 30, 2021 | 225.90 Mn |